Unicycive Therapeutics (UNCY) Current Leases (2021 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Current Leases came in at $598000.0 in Q1 2026, up 9.12% YoY from $548000.0 in Q1 2025, and up 411.11% on a QoQ basis from $117000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) Current Leases (2021 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 6 years of Current Leases data on file, last reported at $598000.0 in Q1 2026.
- Quarterly Current Leases rose 9.12% year-over-year to $598000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $598000.0 (up 9.12% YoY) and the FY2025 annual result came in at $117000.0, down 79.26% from the prior year.
- Current Leases climbed to $598000.0 in Q1 2026, from $117000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $598000.0 in Q1 2026 to a low of $117000.0 in Q4 2025.
- A 5-year average of $329470.6 and a median of $314000.0 in 2023 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases jumped 110.97% — and 2025, when it sank 79.26%.
- Tracing UNCY's Current Leases over 5 years: stood at $155000.0 in 2022, then jumped by 110.97% to $327000.0 in 2023, then surged by 72.48% to $564000.0 in 2024, then tumbled by 79.26% to $117000.0 in 2025, then soared by 411.11% to $598000.0 in 2026.
- The last three Current Leases figures came in at $598000.0 (Q1 2026), $117000.0 (Q4 2025), and $265000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | 616,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 616,000.00 |
| Mar 31, 2026 | 598,000.00 |
| Dec 31, 2025 | 117,000.00 |
| Sep 30, 2025 | 265,000.00 |
| Jun 30, 2025 | 409,000.00 |
| Mar 31, 2025 | 548,000.00 |
| Dec 31, 2024 | 564,000.00 |
| Sep 30, 2024 | 542,000.00 |
| Jun 30, 2024 | 360,000.00 |
| Mar 31, 2024 | 343,000.00 |
| Dec 31, 2023 | 327,000.00 |
| Sep 30, 2023 | 314,000.00 |
| Jun 30, 2023 | 303,000.00 |
| Mar 31, 2023 | 276,000.00 |
| Dec 31, 2022 | 155,000.00 |
| Sep 30, 2022 | 165,000.00 |
| Jun 30, 2022 | 160,000.00 |
| Mar 31, 2022 | 155,000.00 |
| Dec 31, 2021 | 151,000.00 |